Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.